<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO> FR89508-0068 </DOCNO><DOCID>fr.5-08-89.f2.A1067</DOCID><TEXT><ITAG tagnum="69"><ITAG tagnum="41">[Docket No. 89M-0133]</ITAG><ITAG tagnum="56">Sherman Laboratories, Inc.; Premarket Approval of Stay-Wet 3</ITAG><ITAG tagnum="10"><T2>AGENCY: </T2>Food and Drug Administration.</ITAG><ITAG tagnum="10"><T2>ACTION: </T2>Notice.</ITAG><ITAG tagnum="10"><T2>SUMMARY: </T2>The Food and Drug Administration (FDA) is announcingits approval of the application by Sherman Laboratories, Inc., Abita Springs,LA, for premarket approval, under the Medical Device Amendments of 1976,of STAY-WET 3<T4>#</T4> to wet silicone acrylate rigid gas permeable contact lenses.After reviewing the recommendation of the Ophthalmic Devices Panel, FDA'sCenter for Devices and Radiological Health (CDRH) notified the applicant,by letter of March 31, 1989, of the approval of the application.</ITAG><ITAG tagnum="10"><T2>DATE: </T2>Petitions for administrative review by June 7, 1989.</ITAG><ITAG tagnum="10"><T2>ADDRESS: </T2>Written requests for copies of the summary of safetyand effectiveness data and petitions for administrative review to the DocketsManagement Branch (HFA-305), Food and Drug Administration, Rm. 4-62, 5600Fishers Lane, Rockville, MD 20857.</ITAG><ITAG tagnum="10"><T2>FOR FURTHER INFORMATION CONTACT: </T2>David M. Whipple, Center forDevices and Radiological Health (HFZ-460), Food and Drug Administration,8757 Georgia Ave., Silver Spring, MD 20910, 301-427-7940.</ITAG><ITAG tagnum="10"><T2>SUPPLEMENTARY INFORMATION: </T2>On May 6, 1987, Sherman Laboratories,Inc., Abita Springs, LA 70420, submitted to CDRH an application for premarketapproval of STAY-VET 3<T4>#</T4> indicated for use to wet silicone acrylate rigid gas permeablecontact lenses prior to insertion and to lubricate lenses while they areon the eye.On June 21, 1988, the Ophthalmic Devices Panel, an FDA advisory committee,reviewed and recommended approval of the application. On March 31, 1989,CDRH approved the application by a letter to the applicant from the ActingDirector of the Office of Device Evaluation, CDRH.A summary of the safety and effectiveness data on which CDRH based itsapproval is on file in the Dockets Management Branch (address above) andis available from that office upon written request. Requests should beidentified with the name of the device and the docket number found in bracketsin the heading of this document.A copy of all approved labeling is available for public inspection at CDRH_contactDavid M. Whipple (HFZ-460), address above.<ITAG tagnum="84">Opportunity for Administrative Review</ITAG>Section 515(d)(3) of the Federal Food, Drug, and Cosmetic Act (the act)(21 U.S.C. 360e(d)(3)) authorizes any interested person to petition, undersection 515(g) of the act (21 U.S.C. 360e(g)), for administrative reviewof CDRH's decision to approve this application. A petitioner may requesteither a formal hearing under Part 12 (21 CFR Part 12) of FDA's administrativepractices and procedures regulations or a review of the application andCDRH's action by an independent advisory committee of experts. A petitionis to be in the form of a petition for reconsideration under andSection;10.33(b) (21 CFR 10.33(b)). A petitioner shall identify the form of reviewrequested (hearing or independent advisory committee) and shall submitwith the petition supporting data and information showing that there isa genuine and substantial issue of material fact for resolution throughadministrative review. After reviewing the petition, FDA will decide whetherto grant or deny the petition and will publish a notice of its decisionin the <T4>Federal Register. </T4>If FDA grants the petition, the notice willstate the issue to be reviewed, the form of review to be used, the personswho may participate in the review, the time and place where the reviewwill occur, and other details.Petitioners may, at any time on or before June 7, 1989, file with the DocketsManagement Branch (address above) two copies of each petition and supportingdata and information, identified with the name of the device and the docketnumber found in brackets in the heading of this document. Received petitionsmay be seen in the office above between 9 a.m. and 4 p.m., Monday throughFriday.This notice is issued under the Federal Food, Drug, and Cosmetic Act (secs.515(d), 520(h), 90 Stat. 554-555, 571 (21 U.S.C. 360e(d), 360j(h))) andunder authority delegated to the Commissioner of Food and Drugs (21 CFR5.10) and redelegated to the Director, Center for Devices and RadiologicalHealth (21 CFR 5.53).<ITAG tagnum="21">Dated: April 28, 1989.</ITAG><ITAG tagnum="6">Walter E. Gundaker,</ITAG><ITAG tagnum="4">Acting Deputy Director, Center for Devices and Radiological Health.</ITAG><ITAG tagnum="40">[FR Doc. 89-10935 Filed 5-5-89; 8:45 am]</ITAG><ITAG tagnum="68">BILLING CODE 4160-01-M</ITAG></ITAG></ITAG></TEXT></DOC>